Medicare Enrolled

Dr. Lama Hashish, MD

Rheumatology · San Antonio, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
4910 GOLDEN QUAIL, San Antonio, TX 78240
2106909090
In practice since 2006 (19 years)
NPI: 1356432389 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Hashish from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Hashish? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Hashish

Dr. Lama Hashish is a rheumatology in San Antonio, TX, with 19 years in practice. Based on federal Medicare data, Dr. Hashish performed 171,187 Medicare services across 1,725 unique beneficiaries.

Between the years covered by Open Payments, Dr. Hashish received a total of $12,587 from 45 pharmaceutical and/or device companies across 701 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Hashish is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice▲ Top 6% volume in TX$ $12,587 industry payments

Medicare Practice Summary

Medicare Utilization ↗
171,187
Medicare services
Top 6% in TX for rheumatology
1,725
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~9,010 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Certolizumab injection (Cimzia)131,200$4$12
Abatacept infusion (Orencia)30,925$31$63
Denosumab injection (Prolia/Xgeva)3,300$19$32
Injection, ketorolac tromethamine, per 15 mg1,181$0$5
Office visit, established patient (30-39 min)814$87$199
Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle768$54$138
Drug injection, under skin or into muscle697$9$44
Administration of chemotherapy into vein, 1 hour or less505$92$277
Injection, methylprednisolone acetate, 80 mg373$8$20
Infusion, normal saline solution , 1000 cc366$2$5
Aspiration and/or injection of fluid large joint using ultrasound guidance246$89$189
Injection, methylprednisolone acetate, 40 mg159$6$15
Hyaluronan or derivative, orthovisc, for intra-articular injection, per dose150$100$400
Injection, zoledronic acid, 1 mg140$6$15
Injection, methylprednisolone acetate, 20 mg76$4$10
Methotrexate sodium, 50 mg68$2$8
Office visit, established patient (20-29 min)67$65$134
New patient office visit (45-59 min)58$107$308
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less42$45$135
Injection of trigger points, 1-2 muscles29$34$101
Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic23$11$50
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
18.3% high complexity
81.1% medium
0.6% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$12,587
Total received (2018-2024)
Avg $1,798/year across 7 years
Top 27% in TX for rheumatology
45
Companies
701
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$12,533 (99.6%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$54 (0.4%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$1,692
2023
$1,808
2022
$1,469
2021
$1,511
2020
$1,407
2019
$2,440
2018
$2,260

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$1,985
UCB, Inc.
$1,494
Horizon Therapeutics plc
$1,032
ABBVIE INC.
$976
GlaxoSmithKline, LLC.
$800
E.R. Squibb & Sons, L.L.C.
$791
AbbVie, Inc.
$685
PFIZER INC.
$475
Novartis Pharmaceuticals Corporation
$417
Lilly USA, LLC
$377
AbbVie Inc.
$357
Janssen Biotech, Inc.
$315
Boehringer Ingelheim Pharmaceuticals, Inc.
$284
Mallinckrodt Hospital Products Inc.
$267
Radius Health, Inc.
$225
Horizon Pharma plc
$199
Mallinckrodt LLC
$170
Bioventus LLC
$159
Mallinckrodt Enterprises LLC
$156
GENZYME CORPORATION
$135
DePuy Synthes Sales Inc.
$133
Janssen Scientific Affairs, LLC
$125
Fresenius Kabi USA, LLC
$107
Celgene Corporation
$104
Genentech USA, Inc.
$99
ANI Pharmaceuticals, Inc.
$95
Sandoz Inc.
$66
Alexion Pharmaceuticals, Inc.
$58
Antares Pharma, Inc.
$56
Celltrion USA Inc.
$54
Octapharma USA, Inc.
$50
Boston Scientific Corporation
$42
Organon LLC
$38
Ultragenyx Pharmaceutical Inc.
$31
Cumberland Pharmaceuticals, Inc.
$30
AstraZeneca Pharmaceuticals LP
$29
Aurinia Pharma U.S., Inc.
$28
Zyla Life Sciences, Inc.
$24
Medtronic, Inc.
$22
TerSera Therapeutics LLC
$19
SANOFI-AVENTIS U.S. LLC
$19
Bayer HealthCare Pharmaceuticals Inc.
$18
MEDEXUS PHARMA, INC.
$15
Merck Sharp & Dohme Corporation
$14
Fidia Pharma USA Inc.
$14
Top 3 companies account for 35.8% of total payments
Associated products mentioned in payments ›
ACTHAR · AVSOLA · Actemra · Adempas · BENLYSTA · Bimzelx · COSENTYX · CYLTEZO · Cimzia · Crysvita · EVENITY · Enbrel · FORTEO · GELSYN 3 · GELSYN-3 · HADLIMA · HUMIRA · HYM/HYN · HYRIMOZ · Humira · IDACIO · INFLECTRA · INTELLIS ADAPTIVESTIM · KEVZARA · KRYSTEXXA · LUPKYNIS · LYRICA · MONOVISC · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · ORENCIA · ORTHOVISC · Otezla · Otrexup · PURIFIED CORTROPHIN GEL · Quzyttir · RAYOS · REDITREX · REMICADE · RENFLEXIS · RINVOQ · Rasuvo · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · SPECTRA WAVEWRITER · SPRIX · STELARA · Supartz · TALTZ · TEPEZZA · TREMFYA · Tavneos · Tymlos · XELJANZ · YUFLYMA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (100%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $7 per 100 Medicare services performed
Looking for a rheumatology in San Antonio?
Compare rheumatologys in the San Antonio area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
50
Per 100K population
2.5
County median income
$70,571
Nearest hospital
SAN ANTONIO BEHAVIORAL HEALTHCARE HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Hashish is a mixed practice specialist, with above-average Medicare volume (top 6% in TX), and low-engagement industry engagement, with 19 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Hashish experienced with certolizumab injection (cimzia)?
Based on Medicare claims data, Dr. Hashish performed 131,200 certolizumab injection (cimzia) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Hashish receive payments from pharmaceutical companies?
Yes. Dr. Hashish received a total of $12,587 from 45 companies across 701 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Hashish's costs compare to other rheumatologys in San Antonio?
Dr. Hashish's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Hashish) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →